Sandoz has an unwavering commitment to increasing patient access to high-quality, life-enhancing biosimilars. Sandoz is the global market leader and currently markets three biosimilars outside the US, each of which occupies the #1 biosimilar position in its respective category. Sandoz has a leading pipeline with several biosimilars across the various stages of development, including five programs in Phase III clinical trials/filing preparation.
The publication presents an analysis of the US market after the FDA officially approved the first US biosimilar – Zarxio (filgrastim-sndz.
Sandoz comments on the FDA’s proposed rule for Designation of Official Names and Proper Names for Certain Biological Products
November 19, 2015
As the first company to market a biosimilar in the US, Sandoz, a Novartis company, shares the FDA’s commitment to patient safety and to ensuring accurate perceptions of the safety and effectiveness of biological products...
Biosimilars: The Sandoz Way
Joerg Windisch talks about biosimilars development and manufacturing at Sandoz.
Biosimilar medicines offer physicians more choices at affordable prices thereby increasing patient access without increasing overall spending.Read more